Antipsychotic Agents

"Antipsychotic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.

Descriptor ID	D014150
MeSH Number(s)	D27.505.696.277.950.040 D27.505.954.427.210.950.040 D27.505.954.427.700.872.331
Concept/Terms	Antipsychotic Agents Antipsychotic Agents Agents, Antipsychotic Antipsychotics Major Tranquilizers Tranquilizers, Major Tranquillizing Agents, Major Agents, Major Tranquillizing Major Tranquillizing Agents Neuroleptic Drugs Drugs, Neuroleptic Neuroleptics Tranquilizing Agents, Major Agents, Major Tranquilizing Major Tranquilizing Agents Antipsychotic Drugs Drugs, Antipsychotic Neuroleptic Agents Agents, Neuroleptic Antipsychotic Effect Antipsychotic Effect Effect, Antipsychotic Antipsychotic Effects Effects, Antipsychotic

Below are MeSH descriptors whose meaning is more general than "Antipsychotic Agents".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Central Nervous System Depressants [D27.505.696.277]
Tranquilizing Agents [D27.505.696.277.950]
Antipsychotic Agents [D27.505.696.277.950.040]
Therapeutic Uses [D27.505.954]
Central Nervous System Agents [D27.505.954.427]
Central Nervous System Depressants [D27.505.954.427.210]
Tranquilizing Agents [D27.505.954.427.210.950]
Antipsychotic Agents [D27.505.954.427.210.950.040]
Psychotropic Drugs [D27.505.954.427.700]
Tranquilizing Agents [D27.505.954.427.700.872]
Antipsychotic Agents [D27.505.954.427.700.872.331]

Below are MeSH descriptors whose meaning is related to "Antipsychotic Agents".

Below are MeSH descriptors whose meaning is more specific than "Antipsychotic Agents".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Antipsychotic Agents" by people in this website by year, and whether "Antipsychotic Agents" was a major or minor topic of these publications.

Bar chart showing 47 publications over 19 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	3	0	3
1999	1	0	1
2002	1	0	1
2003	1	1	2
2004	2	0	2
2005	0	2	2
2006	2	1	3
2007	2	1	3
2008	4	2	6
2009	1	1	2
2010	2	1	3
2011	3	1	4
2012	3	2	5
2013	1	0	1
2014	3	0	3
2017	2	0	2
2018	1	0	1
2019	1	1	2
2020	1	0	1

Below are the most recent publications written about "Antipsychotic Agents" by people in Profiles.

Jerome RN, Pulley JM, Sathe NA, Krishnaswami S, Dickerson AB, Worley KJ, Wilkins CH. Exploring Biologic Predictors Response Disparities to Atypical Antipsychotics among Blacks: A Quasi-Systematic Review. Ethn Dis. 2020; 30(Suppl 1):229-240.

View in: PubMed
Hassanzadah M, Bitar AH, Khanfar NM, Khasawneh FT, Lutfy K, Shankar GS. A retrospective cohort study of the prevalence of anxiety and agitation in schizophrenic smokers and the unmet needs of smoking cessation programs. Medicine (Baltimore). 2019 Oct; 98(40):e17375.

View in: PubMed
Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019 04; 179:55-62.

View in: PubMed
Maestri TJ, Mican LM, Rozea H, Barner JC. Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission? Psychopharmacol Bull. 2018 03 13; 48(3):8-15.

View in: PubMed
Ralat SI, Depp CA, Bernal G. Reasons for Nonadherence to Psychiatric Medication and Cardiovascular Risk Factors Treatment Among Latino Bipolar Disorder Patients Living in Puerto Rico: A Qualitative Study. Community Ment Health J. 2018 08; 54(6):707-716.

View in: PubMed
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao SD, Pilkinton PD, Wilcox JA, Iranmanesh A, Sapra M, Jurjus G, Michalets JP, Aslam M, Beresford T, Anderson KD, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D'Souza DC, Larson G, Anderson WG, Klatt M, Fareed A, Thompson SI, Carrera CJ, Williams SS, Juergens TM, Albers LJ, Nasdahl CS, Villarreal G, Winston JL, Nogues CA, Connolly KR, Tapp A, Jones KA, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda AR, Niculescu AB, Fischer BA, Loreck DJ, Rosenlicht N, Lieske S, Finkel MS, Little JT. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017 Jul 11; 318(2):132-145.

View in: PubMed
Takeshita J, Goebert D, Else I, Carlton B, Matsu C, Guerrero A. Atypical antipsychotic usage among Asian Americans and Pacific Islanders. Hawaii J Med Public Health. 2014 Sep; 73(9):288-91.

View in: PubMed
Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 01; 24(17):4294-7.

View in: PubMed
Bricker B, Sampson D, Ablordeppey SY. Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. Pharmacol Biochem Behav. 2014 May; 120:109-16.

View in: PubMed
Warren KR, Buchanan RW, Feldman S, Conley RR, Linthicum J, Ball MP, Liu F, McMahon RP, Gorelick DA, Huestis MA, Kelly DL. Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study. J Clin Psychopharmacol. 2013 Feb; 33(1):118-20.

View in: PubMed

People

Explore

Similar Concepts

Top Journals